Nicholas J Vogelzang, MD, FASCO, FACP

Specialties

Dr. Vogelzang is a renowned medical oncologist and cancer researcher who has authored/​coauthored numerous peer-​reviewed articles, book chapters and abstracts and has given hundreds of lectures and presentations to his peers. From 1999 to 2003, Dr. Vogelzang was Professor and Director of the University of Chicago Cancer Research Center. He also served as Director of Nevada Cancer Institute from 2004 to 2009. Dr. Vogelzang joined Comprehensive Cancer Centers of Nevada as a medical oncologist in 2009. He serves as Medical Director for US Oncology Research Executive Committee and is the Associate Chair for the Genitourinary and Developmental Therapeutics Programs. He is also Associate Editor of Kidney Cancer Journal and Clinical Genitourinary Cancer.

Dr. Vogelzang leads cutting-​edge clinical trials in genitourinary malignancies and mesothelioma and is involved in new therapies for patients with metastatic kidney cancer. He has lead research in Las Vegas for two recent FDA-​approved prostate cancer treatments — Provenge and Xofigo and was recently published in Nature for his research on an anti-​PD-​L1 treatment for metastatic bladder cancer.